They seemed to be deemphasizing previous indications and are now trying to highlight possible utility in prostate cancer. I'm kind of surprised they are putting most their eggs in the XL174 basket, as this is the compound that was just returned by BMS 2 years after they paid $200M upfront. Not a good sign. The new CEO is an R&D guy without a commercial background who was promoted after Scangos left for Biogen. Looks like they are going to plow forward and spend all the remaining money on a new potential indication for a failed compound.
I don't think they were de-emphasizing other indications, those had been talked about repeatedly in the past. It's time to talk something new from RDT.
HRPC is interesting. Data are early so far. It will be interesting to see full RDT data in Nov. No agent has shown dual activities against both soft tissue metastases and bone metastases. If this is true, that's differentiation.